» Articles » PMID: 35782494

A Progress Report and Roadmap for Microphysiological Systems and Organ-On-A-Chip Technologies to Be More Predictive Models in Human (Knee) Osteoarthritis

Overview
Date 2022 Jul 5
PMID 35782494
Authors
Affiliations
Soon will be listed here.
Abstract

Osteoarthritis (OA), a chronic debilitating joint disease affecting hundreds of million people globally, is associated with significant pain and socioeconomic costs. Current treatment modalities are palliative and unable to stop the progressive degeneration of articular cartilage in OA. Scientific attention has shifted from the historical view of OA as a wear-and-tear cartilage disorder to its recognition as a whole-joint disease, highlighting the contribution of other knee joint tissues in OA pathogenesis. Despite much progress in the field of microfluidic systems/organs-on-a-chip in other research fields, current models in use do not yet accurately reflect the complexity of the OA pathophenotype. In this review, we provide: 1) a detailed overview of the most significant recent developments in the field of microsystems approaches for OA modeling, and 2) an OA-pathophysiology-based bioengineering roadmap for the requirements of the next generation of more predictive and authentic microscale systems fit for the purpose of not only disease modeling but also of drug screening to potentially allow OA animal model reduction and replacement in the near future.

Citing Articles

Exploring Osteoarthritis Dynamics: Patient-Specific Cartilage Samples in an Organ-on-a-Chip Model.

Pasztorek M, Fischer J, Otahal A, de Luna A, Nehrer S, Rosser J Cartilage. 2024; :19476035241277654.

PMID: 39235338 PMC: 11569566. DOI: 10.1177/19476035241277654.


Revolutionizing renal research: The future of kidney-on-a-chip in biotechnology.

Nishimura Y Regen Ther. 2024; 26:275-280.

PMID: 38993536 PMC: 11237358. DOI: 10.1016/j.reth.2024.06.006.


A personalized osteoarthritic joint-on-a-chip as a screening platform for biological treatments.

Petta D, DArrigo D, Salehi S, Talo G, Bonetti L, Vanoni M Mater Today Bio. 2024; 26:101072.

PMID: 38757057 PMC: 11097088. DOI: 10.1016/j.mtbio.2024.101072.

References
1.
Weinberger A, Simkin P . Plasma proteins in synovial fluids of normal human joints. Semin Arthritis Rheum. 1989; 19(1):66-76. DOI: 10.1016/0049-0172(89)90087-5. View

2.
Salgado C, Jordan O, Allemann E . Osteoarthritis In Vitro Models: Applications and Implications in Development of Intra-Articular Drug Delivery Systems. Pharmaceutics. 2021; 13(1). PMC: 7824837. DOI: 10.3390/pharmaceutics13010060. View

3.
Sellam J, Berenbaum F . Is osteoarthritis a metabolic disease?. Joint Bone Spine. 2013; 80(6):568-73. DOI: 10.1016/j.jbspin.2013.09.007. View

4.
Xue X, Zhang T, Cui S, He D, Wang X, Yang R . Sexual dimorphism of estrogen-sensitized synoviocytes contributes to gender difference in temporomandibular joint osteoarthritis. Oral Dis. 2018; 24(8):1503-1513. DOI: 10.1111/odi.12905. View

5.
Cloyd J, Malhotra N, Weng L, Chen W, Mauck R, Elliott D . Material properties in unconfined compression of human nucleus pulposus, injectable hyaluronic acid-based hydrogels and tissue engineering scaffolds. Eur Spine J. 2007; 16(11):1892-8. PMC: 2223355. DOI: 10.1007/s00586-007-0443-6. View